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Background: Genetic susceptibility to tobacco smoke might modify the effect of smoking on pregnancy outcomes.
Methods: We conducted a case–control study of 543 women who delivered singleton live births in Kaunas
(Lithuania), examining the association between low-level tobacco smoke exposure (mean: 4.8 cigarettes/day) during
pregnancy, GSTT1 and GSTM1 polymorphisms and birthweight of the infant. Multiple linear-regression analysis was
performed adjusting for gestational age, maternal education, family status, body mass index, blood pressure, and
parity. Subsequently, we tested for the interaction effect of maternal smoking, GSTT1 and GSTM1 genes
polymorphisms with birthweight by adding all the product terms in the regression models.
Results: The findings suggested a birthweight reduction among light-smoking with the GSTT1–null genotype
(−162.9 g, P = 0.041) and those with the GSTM1–null genotype (−118.7 g, P = 0.069). When a combination of these
genotypes was considered, birthweight was significantly lower for infants of smoking women the carriers of the
double-null genotypes (−311.2 g, P = 0.008). The interaction effect of maternal smoking, GSTM1 and GSTT1
genotypes was marginally significant on birthweight (−234.5 g, P = 0.078). Among non-smokers, genotype did not
independently confer an adverse effect on infant birthweight.
Conclusions: The study shows the GSTT1–null genotype, either presents only one or both with GSTM1–null
genotype in a single subject, have a modifying effect on birthweight among smoking women even though their
smoking is low level. Our data also indicate that identification of the group of susceptible subjects should be based
on both environmental exposure and gene polymorphism. Findings of this study add additional evidence on the
interplay among two key GST genes and maternal smoking on birth weight of newborns.
Keywords: Birthweight, GST polymorphisms, Smoking, InteractionBackground
Environmental factors contributing to reduced birth-
weight are a great concern because of the well-known
relation of birthweight to infant mortality and adverse
health effects in later life. Recent epidemiological studies
have linked maternal tobacco-smoking and other envir-
onmental exposures to increased risk of low birth
weight, preterm delivery, congenital anomalies, preg-
nancy loss, foetal growth, birthweight [1,2]. Investigators,* Correspondence: r.grazuleviciene@gmf.vdu.lt
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distribution, and reproduction in any mediumwho have examined the issue, showed dose–response
gradients in relation to the number of cigarettes smoked
[3] and association between maternal smoking during
pregnancy, impaired foetal growth and overweight in
childhood [4]. Some studies reported an increased risks
of low birth weight (LBW) and small for gestational age
with heavier maternal smoking (> 10 cigarettes/day), as
well as noting an increased risk for "very preterm" birth
(< 35 weeks) [3]. It was reported that smoking even 20
cigarettes/day was not related to risk of preterm birth
overall, but cotinine measured at the time of delivery
was. A clear association and dose–response gradient was
present for risk of foetal growth restriction [5] andentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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even in cases of a "minimal" consumption of 1–5 cigar-
ettes per day. It was estimated that approximately 30%
of growth-restricted neonates could be independently
associated with maternal smoking [7].
Low birth weight of infant is recognised to be asso-
ciated with demographic and environmental factors;
however, tobacco-smoking remains the most important
modifiable risk factor for foetal-growth restriction [8].
Maternal smoking during pregnancy, for heavy smokers,
results in an approximately 150- to 245-g reduction in
the average birthweight of infants [3,9,10], however, it is
generally accepted that there is no safe level of exposure
to cigarette smoke [11]. In infants birthweight decreased
as the mother’s smoking increased, but the differences
comparing 1–5 cig/day vs. 6–10 cig/day were not signifi-
cant [6]. One of the explanations of tobacco smoking in-
fluence on infants birthweight is that individual genetic
susceptibility to tobacco smoke might also have an effect
on the foetal development [12]; – moreover, this vari-
ability may be related to the interplay of environmental
exposures, such as exposure to cigarette smoke, and
host-modified metabolic processes [13].
Several recent studies have represented the investiga-
tions how genetic susceptibility modulates risk of birth-
weight, infant birth size, small-for-gestational-age from
environmental exposures such as cigarette smoke [13-16].
Numerous chemical compounds such as polycyclic aro-
matic hydrocarbons (PHA) in tobacco smoke are activated
and detoxified by xenobiotic-metabolizing enzymes, such
as glutathione S-transferase (GST) complex. Glutathione
S-transferase M1 (GSTM1) is involved in the detoxifica-
tion of a large number of xenobiotics [17,18]. The genetic
polymorphism of GSTM1 may be a factor in determining
the individual’s susceptibility to the toxic effects of various
xenobiotics, tobacco smoke being one among them. The
deficiency of GSTM1 has been shown to impaired enzyme
activities, increase DNA-adduct formation and cytogenic
damage [14,19], and increase the susceptibility to both
tobacco-smoke xenobiotics and small-for-gestational-age
[16,20]. GSTM1 gene polymorphism is found to be
present in 40 to 60% of most populations [17].
GSTT1-encoded enzymes catalyses the detoxification of
xenobiotics, it is probable that GSTT1 plays a protective
role against cell damage. The GSTT1-encoded enzymes
are involved in the metabolism and detoxification of
PAHs. It is possible that GST induction represents part of
an adaptive response mechanism to chemical stress [20].
The frequency of the GSTT1–null allele has been reported
to be 30 to 40% in Germany [21], whereas in a Swedish
population, it is only 10% [22].
GSTM1 and GSTT1 null genes are the result of two
homozygous deletions that result in a loss of functional
activity [23]. Studies of the interaction between genesand toxic chemical exposure indicate that the GSTM1–
null and GSTT1–null genotypes have been associated
with the effect of maternal smoking on duration of ges-
tation, birth weight, and size [13,14,16]. Several recent
studies have reported that genetic susceptibility modu-
lates the risk of adverse pregnancy outcomes from
tobacco smoke [15,16,24-31].
Different results have been presented by several authors
[16]. In a case–control study, controlling for several con-
founding factors, the authors have shown that the mater-
nal GSTT1–null genotype had a 1.6-fold reduced risk of
infant-growth restriction. However, after adjustment for
maternal smoking (categories less than 10 cigarettes per
day and more than 10 cigarettes per day), the results are
not statistically significant. There is evidence that the ef-
fect of cigarette-smoke exposure depends on the popula-
tion characteristics: among the Japanese, the GSTM1–null
genotype decreases foetal growth but this effect is not
observed in Caucasians [3,14].
Tobacco smoke is a complex mixture of numerous
substances that include polycyclic aromatic hydrocar-
bons (PAHs) and N-nitrosamines among them. Recent
studies have shown that there are significant associations
between exposure to PAHs and reduced foetal growth and
preterm birth [1]. Increasing PAH levels during pregnancy
may increase the risk of foetal growth restriction [32],
lung- function reduction in children, particularly for those
whose mothers possessed the polymorphic CYP1A1*2A
and GSTM1 deletion [26]. However, there is inconsistency
in the relationship between GSTT1 and GSTM1 poly-
morphisms and smoking effects on foetal development.
Variations in the CYP1A1 and GSTM1 genes that encode
these enzymes could affect smoking behaviour by altering
the levels and duration of tobacco-related PAHs and their
metabolites in the body [33].
Although separate GSTM1 and GSTT1 gene deletions
are well-studied functional variants, so far, there are only
a limited numbers of studies published on the impacts
of light cigarette smoking, GST metabolic gene poly-
morphism, and infant birth weight data.
In this study, we used a case–control design to examine
the relationship between maternal smoking, GSTM1,
GSTT1 polymorphism, and birth weight. We hypothesized
those women with the GSTM1– and GSTT1– null geno-
type who are exposed to cigarette smoke during pregnancy
are at elevated risk for newborn birthweight reduction.
Methods
Participant and outcome assessment
A prospective cohort study of pregnant women was con-
ducted between 2007 and 2008 in Kaunas, Lithuania
(Kaunas HiWATE cohort study). On their first visit to a
general practitioner, all pregnant women living in Kaunas
were invited to join the cohort and answer to the first
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spective cohort study, enrolling them at 23–35 weeks of
gestation at the four prenatal care clinics affiliated to the
hospitals of the Kaunas University of Medicine. Participa-
tion was on a voluntary basis and the women were en-
rolled in the study only if they consented to participate in
the cohort. The research protocol was approved by the
Lithuanian Bioethics Committee and informed consent
was obtained from all subjects. A special questionnaire
was evolved to interview the women who agreed to par-
ticipate in the genetic study and blood samples for gen-
etic analysis was collected. Details of the methods and
study subjects have been published elsewhere [34]. The
subjects of this case–control study were 543 women,
who delivered singleton live births at the four hospitals
affiliated to the Lithuanian University of Health Science.
Multiple births or newborns with major births defects
were excluded.
Pregnant women of the cohort were asked to answer
second questionnaire provided to them at the clinic be-
fore delivery. The interview contained a number of vari-
ables including demographics (age, education and family
status); reproductive history (miscarriage); job character-
istics; self-reported psychosocial stress; health behaviour;
diseases; maternal smoking; paternal smoking. The self-
reported stress of the respondents was assessed by the fol-
lowing thesis: “My daily activities are very trying and
stressful”. Four respondent options were used to define
stress: this describes my state (1) very well, (2) fairly well,
(3) not very well, (4) not at all. Values 1 and 2 were consid-
ered to represent stress; 3 and 4 represented no stress.
The women were followed up with regard to pregnancy
outcomes by the research staff. Pregnancy outcomes were
ascertained chiefly from computerised hospital admission
files and by abstraction of medical records. In this study,
infant birthweight was measured in the delivery room by a
trained nurse and was accurate to 1 g. The age of gestation
was calculated using the data of birth as reported on the
birth certificate and the 1st day of the last menstrual
period as was ascertained at first interview, and by ultra-
sound examination.
Smoking exposure
Data regarding smoking behaviour were acquired
through face-to-face interviewing. The trained research
assistant in person in the hospital setting asked the
women to report their daily cigarette consumption both
before and during pregnancy. Woman had to answer the
questions, “How many cigarettes did you smoke before
pregnancy?” and “How many cigarettes did you smoke
during pregnancy?” A mother was defined as smokers if
she reported smoking at least one cigarette per day dur-
ing pregnancy. In this study, data on mothers were cate-
gorised into two groups with respect to their cigarettesmoking habits: those who did not smoke and those
women who continue smoking during pregnancy. The
parent was defined as a smoker if he smoked at least
one cigarette per day. To assess smoking level we calcu-
lated the mean number cigarettes smoked per day.
Genotyping
The genomic DNA was extracted according to a standard
protocol. The gene GSTM1– null (GenBank accession no.
X68676) and GSTT1–null (GenBank accession no.
AP000351) genotypes were identified by the multiplex
polymerase chain reaction (PCR) in peripheral blood
DNA samples. The details of this method for the detection
of polymorphism of GSTT1 and GSTM1 can be found
elsewhere [35]. This method allows the detection of the
presence of the genotype (at least 1 allele present: AA or
Aa) or its absence (complete deletion of both alleles: aa).
Maternal blood samples were collected in vials contain-
ing EDTA and stored at a temperature of −20°C. DNA
was purified from the peripheral blood using DNA purifi-
cation kits (MBI “Fermentas”, Vilnius, Lithuania). DNA
concentrations were quantified with a spectrophotom-
eter (Eppendorrf BioPhotometer, 61310488, Hamburg,
Germany). A PCR-based study of GSTM1 and GSTT1
polymorphism was carried out according to the method
described previously [24]. The research staffs were blinded
to outcome. The primers used for PCR were as follows:
GSTM1 forward50-GAA CTC CCT GAA AAG CTA AAG
C-30and reverse 50-GTT GGG CTC AAA TAT ACG GTG
G-30; GSTT1 forward 50-TTC CTT ACT GGT CCT CAC
ATC TC-30 and reverse 50-TCA CCG GAT CAT GGC
CAG CA-30. As internal control, a 268-bp fragment of the
human β-globin gene (GenBank accession no. U01317)
was coamplified with a second set of primers (50-CAA
CTT CAT CCA CGT TCA CC-30) and (50-GAA GAG
CCA AGG ACA GGTAC- 30) (Biomers.net – the biopoly-
mer factory, Germany). PCR was carried out in a final vol-
ume of 25 μl. The procedure followed for PCR was:
primary denaturation at 94°C for 5 min, denaturation at
94°C for 1min, annealing at 60°C for 1 min, extension at
72°C for 1 min, 30 cycles were conducted. Final extension
was at 72°C for 10 min. The PCR products were electro-
phoresed in 2% agarose gels and stained in ethidium
bromide. The DNA bands were visualised by UV transillu-
mination (EASY Win32, Herolab, Germany). GSTM1 and
GSTT1 polymorphisms were coded as present (GSTM1–1
and GSTT1–1) or null (GSTM1–0 and GSTT1–0). To con-
firm the analyses we repeated genotyping for GSTM1 and
for GSTT1 in 150 subjects. The genotyping consistency
rates were 100% for both GSTM1 and GSTT1.
Statistical methods
We first examined the associations between the mater-
nal characteristics and smoking status during pregnancy,
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dent’s t-test. We then used multiple linear-regression
models to estimate the association of maternal cigarette
smoking during pregnancy and the maternal genetic
polymorphism in relation to birthweight of the newborn,
with adjustment for major covariates. These included
prepregnancy body mass index (BMI = weight/height2),
blood pressure, parity, gestational age, education and
family status. The Mantel – Haenszel test was used to
test the interaction between GSTTI and GSTM1 on ma-
ternal smoking. Results from these association analyses
were further verified using regression models to test the
associations of GSTT1 GSTM1 and maternal smoking,
including the effect from the interaction between the
two genes. The subgroups were defined for maternal
smoking status during pregnancy (no vs. yes) and geno-
types for GSTT1 (null vs. present) and GSTM1 (null vs.
present). We tested the gene–cigarette smoke inter-
action effect for birthweight reduction by adding all the
product term (both 2-way and 3-way terms) in the
model adjusting for potential effect modifiers. In the
analyses, beta (β) represents the difference in mean
birthweight (continuous variable) for cigarette smoking
between the variant genotype after adjustment for the
selected effect modifiers. Statistical significance was
defined as P < 0.05. All statistical analyses were carried
out using the SPSS software for Windows version 12.0.1.
Results
The analysis included 543 pregnant women: 460 non-
smokers and 83 continuous smokers during pregnancy.
The mean number cigarettes smoked per day were 4.8.
Before pregnancy smoked 140 (25.7%) study subjects,
among them 42.9% continuous smokers during preg-
nancy and 57.1% non-smokers during pregnancy. Preva-
lence of passive smoking at home (husband smoking)
among continuous smokers during pregnancy was 91%
and among non-smokers during pregnancy it was 50.4%.
A total of 95.9% women were Lithuanian and the 2
groups did not differ in ethnicity.
We also conducted analyses comparing questionnaire
data and birth certificate data on various characteristics
among participants and non-participants. The mean
birthweight and gestational duration were similar among
the two groups. These two groups did not differed by
ethnic group, however, non-participating mothers were
younger, less educated (did not graduate from university,
46.6% vs. 54.3%), more often smokers (smokers, 9.6% vs.
6.9%), and did have fewer prior births (no child, 64.1%
vs. 45.1%), than that of participants.
We found that among 543 participant, 450 (82.9%)
possessed at least one copy of the functional gene,
GSTT1–plus genotype and the remaining 93 (17.1%) had
the GSTT1–null genotype. The GSTM1 gene among 543study subjects, 293 (54%) possessed at least one copy of
the functional gene, GSTM1–plus genotype and the
remaining 250 (46.0%) had the GSTM1–null genotype.
The carriers of the double-null genotypes comprised
8.7% of the total population studied. For the GSTM1
and GSTT1 polymorphisms, we were unable to deter-
mine whether they were in Hardy-Weinberg equilibrium
because heterozygous individuals could not be distin-
guished from homozygous wild type.
Maternal characteristics with reference to the tobacco
smoke exposure status are presented in Table 1. The
nonexposed and exposed groups were similar in terms
of the maternal prepregnancy BMI, hypertension, per-
ceived stress, history of miscarriage, parity, sex of infant,
and ethnic group, whereas the two groups differed with
reference to maternal age, education and family status
(P < 0.001). The mean birthweight of the infants was
3399.0 g for the nonexposed group and that for the
exposed group was 3284.1 g, but there was no statisti-
cally significant difference (P = 0.132). The mean gesta-
tional age was 38.9 weeks for the both groups. In terms of
the frequency of the GSTM1–null genotype, women in
the group exposed to tobacco smoke and the group non-
exposed were similar (41.0% and 47.0%, P = 0.340),
whereas the GSTT1–null genotype was found in 26.5% of
the smokers and in 15.4% of the non-smokers (P = 0.018).
Table 2 presents the influence of maternal characteris-
tics on the birthweight of the infants as the difference in
mean birthweight in relation to the maternal characteris-
tics listed in each row.
The characteristics that positively affected the crude
mean birthweight were increased BMI, hypertension and
gestational age. Low levels of education, not married sta-
tus and previous preterm were associated with reduction
in the mean birthweight. In terms of the GSTM1– and
GSTT1– genotype frequencies, there was no significant
influence on the crude birthweight of infants. After ad-
justment for the BMI, gestational age and loss outliers, the
maternal characteristics that affected the reduction in birth-
weight were as follows: low education levels (−155.3 g),
maternal smoking during pregnancy (−137.0 g), parental
smoking (−93.3 g) and GSTT1–null genotype in smokers
(−211.8 g, P = 0.036). When both GSTT1– and GSTM1–
null genotypes were considered, continuous maternal
smoking during pregnancy was associated with a mean re-
duction of 340.4 g (P = 0.016) in birthweight of infants.
Table 3 presents the crude and adjusted combined asso-
ciations of continuous maternal smoking during preg-
nancy and maternal GSTT1 and GSTM1 genotypes with
reference to infant birthweight, where β represents the dif-
ference in mean birthweight between each subgroup and
the reference group.
After complete adjustment for gestational age, BMI,
education, family status, parity and hypertension, the




Maternal smoking status during pregnancy
Non-smoking (n=460) Smoking (n=83) P-value
Maternal age, mean (SD), years 29.0 (5.0) 26.4 (5.7) < 0.001
Maternal height, mean (SD), cm 167.6 (5.7) 167.3 (7.2) 0.703
Maternal weight, mean (SD), kg 75.3 (12.5) 77.4 (15.2) 0.250
BMI, mean (SD) 26.8 (4.3) 27.6 (4.8) 0.136
Gestational age, mean (SD), weeks 38.9 (2.2) 38.9 (2.2) 0.979
Birthweight, mean (SD), g 3399.0 (639.2) 3284.1 (632.5) 0.132
Birth length, mean (SD), cm 51.3 (3.1) 50.8 (3.5) 0.150
Infant sex, n (%)
male 245 (53.3) 47 (56.6) 0.737
female 213 (46.3) 36 (43.4)
Education, n (%)
university, college 437 (95.0) 53 (63.9) <0.001
≤ 12 years 23 (5.0) 30 (36.1)
Marital status, n (%)
married 377 (82.0) 40 (48.2) <0.001
not married 83 (18.0) 43 (51.8)
Parity, n (%)
1st 217 (47.2) 38 (45.8) 0.905
2nd and more 243 (52.8) 45 (54.2)
Miscarriage, n (%)
no prior 369 (80.2) 70 (84.3) 0.450
yes 91 (19.8) 13 (15.7)
Blood pressure, n (%)
< 120/80 mm/Hg 324 (70.4) 56 (67.5) 0.604
> 120/80 mm/Hg 136 (29.6) 27 (32.5)
Stress, n (%)
no 379 (82.4) 64 (77.1) 0.281
yes 81 (17.6) 19 (22.9)
Ethnic group, n (%)
Lithuanian 441 (95.9) 80 (96.4) 0.571
other 19 (4.1) 3 (3.6)
Passive smoking
Yes 235 (50.4) 75 (91.0) <0.001
No 225 (49.6) 8 (9.0)
GSTT1, n (%)
present 389 (84.6) 61 (73.5) 0.018
null 71 (15.4) 22 (26.5)
GSTM1, n (%)
present 244 (53.0) 49 (59.0) 0.340
null 216 (47.0) 34 (41.0)
SD standard deviation of the variability of individual observations.
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Table 2 Influence of maternal characteristics on infant’s birthweight assessed by the crude and adjusted coefficient
ß in linear regression (n=539†)
Maternal characteristics continuous and binary ß crude SE P-value ß*adjusted SE P-value
BMI** 42.7 6.0 <0.001
Gestational age, week** 191.0 9.2 <0.001
Age < 20 or > 30 years −34.2 56.7 0.547 −11.43 41.3 0.783
Low education, ≤ 12 years −279.7 91.7 0.002 −155.3 67.2 0.021
Not married −148.9 64.7 0.022 −87.1 47.2 0.066
Parity 2nd and more 49.5 55.0 0.368 90.8 39.9 0.023
Miscarriage 15.2 69.7 0.828 4.0 50.8 0.937
Previous preterm −400.1 135.2 0.003 82.5 100.0 0.409
Maternal stress −94.7 70.7 0.181 5.4 51.6 0.916
Blood pressure > 120/80 mm/Hg 189.4 76.6 0.014 87.5 59.0 0.139
Maternal smoking −114.9 76.1 0.132 −137.0 55.2 0.013
Parental smoking −86.9 55.0 0.115 −93.3 40.1 0.020
GSTT1 null vs present −104.1 72.7 0.153 −72.7 52.7 0.170
GSTM1 null vs present −25.3 55.1 0.646 −26.0 40.0 0.516
GSTT1 null & smoking −207.0 138.9 0.137 −211.8 100.8 0.036
GSTM1 null & smoking −60.4 113.3 0.594 −150.2 82.4 0.069
GSTT1 & GSTM1 null and smoking −294.0 194.4 0.131 −340.4 141.2 0.016
ß represent the difference in mean birthweight for maternal characteristics in each row.
ß*adjusted for body mass index, gestational age and loss outlier.
**Continuous variable.
SE standard error of the difference between the means.
† Excluded outliers.
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able) for continuous smokers was 83.4 g (P = 0.073).
Among non-smoking mothers, the GSTT1–null genotype
alone did not confer a significant adverse effect on birth-
weight (−22.6 g, P = 0.345). The findings suggested a birth-
weight reduction among low-level smoking mothers with
the GSTT1–null genotype (−162.9 g, P = 0.041). Maternal
smoking was associated with a mean reduction of 58.8 g in
birthweight for the GSTM1–plus and 118.7 g, P = 0.069
for the GSTM1–null genotypes; nevertheless, there was no
statistically significant difference. When a combination of
these genotypes was considered, a modifying effect was
revealed and birthweight was significantly lower for infants
of smoking women carriers of the double-null genotypes
(−311.2 g; P = 0.008). The interaction effect of maternal
smoking, GSTM1 and GSTT1 genotypes was marginally
significant on birthweight (−234.5 g; P = 0.078).
Discussion
In this molecular epidemiological study on maternal
cigarette smoking and genetic determinants of xeno-
biotic metabolism, we found some evidence that the
effects of maternal smoking on infant birthweight were
modified by the maternal GSTT1 and GSTM1 genotypes.
This study shows that even light maternal smoking
(mean: 4.8 cigarettes/day) has an increased risk for infantbirthweight reduction among genetically susceptible
woman. Smokers with the variant GSTT1–null genotype
had babies with lower mean birthweight (162.9 g) than
non-smokers with the same genotype (P = 0.041), while
smokers with the variant GSTM1–null genotype had ba-
bies with lower mean birthweight (118.7 g) than non-
smokers with the same genotype (P = 0.069). We also
found a gene-gene interaction among smokers. A combin-
ation of the GSTM1–null and the GSTT1–null genotypes
has been found to exacerbate the effect of maternal expos-
ure to tobacco-smoking on the birthweight of infants
more than the presence of either genotype alone: −311.2 g,
P = 0.008 in smokers vs. 10.1 g, P = 0.447 in non-smokers.
An interaction effect of maternal smoking, GSTM1 and
GSTT1 genotypes was marginally significant on birth-
weight (−234.5 g, P = 0.078). All associations were assessed
after a number of relevant covariates were statistically con-
trolled. These data and previous studies reported findings
[18] suggest that the observed reductions in infants’ birth-
weight from this sample could be related to the main
effects of prenatal exposure to tobacco.
Consistent with earlier studies, we found that maternal
cigarette-smoking reduced the birthweight of infants
[8,36] and that infant birthweight may vary in relation to
gestational age, BMI, parity, and other variables of the
population considered in the corresponding study [5,37].
Table 3 Associations between maternal smoking during pregnancy and infant birthweight by maternal GSTT1
and GSTM1 genotype assessed by the crude and adjusted coefficient ß in linear regression
Genotype Smoking status during pregnancy Birthweight, g Birthweight, g β+ crude (SE) P Birthweight, g β++ adjusted (SE) P Birthweight, g β++ adjusted (SE) P
Total sample Non-smoking (n = 456) 3390.3 Referent Referent Referent
Smoking (n = 83) 3284.1 −86.5 (57.5) 0.066 −83.4 (57.1) 0.073 −83.4 (57.1) 0.073
GSTT1
Present Non-smoking (n = 385) 3401.4 Referent Referent Referent
Present Smoking (n = 61) 3320.7 −70.4 (65.7) 0.143 −72.3 (65.1) 0.134 −38.8 (57.6) 0.250
Null Non-smoking (n = 71) 3330.0 Referent Referent −22.6 (57.6) 0.345
Null Smoking (n = 22) 3182.9 −115.9 (129) 0.186 −123.7 (131) 0.175 −162.9 (93.0) 0.041
*Interaction: smoking × GSTT1-null −111.9 (123.1) 0.182 −96.8 (122.5) 0.215
GSTM1
Present Non-smoking (n = 242) 3413.6 Referent Referent Referent
Present Smoking (n = 49) 3255.9 −87.2 (73.9) 0.119 −85.1 (74.2) 0.126 −58.8 (66.1) 0.187
Null Non-smoking (n = 214) 3363.9 Referent Referent −32.4 (41.2) 0.216
Null Smoking (n = 34) 3324.8 −97.1 (92.0) 0.146 −100.6 (90.2) 0.133 −118.7 (79.6) 0.069
*Interaction: smoking ×GSTM1-null −17.0 (106.1) 0.437 −26.6 (105.6) 0.400
GSTT1 & GSTM1
Present Non-smoking n = 207) 3429.4 Referent Referent Referent
Present Smoking (n = 38) 3251.2 −137.9 (82.3) 0.048 −135.5 (82.6) 0.051 −84.7 (71.2) 0.118
Null Non-smoking (n = 36) 3339.7 Referent Referent 10.1 (76.1) 0.447
Null Smoking (n = 11) 3093.5 −318.0 (198) 0.058 −320.8 (203) 0.061 −311.2 (128) 0.008
*Interaction: smoking ×GSTT1–null ×GSTM1–null - 240.3 (164) 0.072 −234.5 (164.3) 0.078
ß represent the difference in mean birth weight for cigarette smoking between the variant genotype.
+ ß crude.
++ ß after adjustment for the covariates: gestational age, body mass index, education, family status, parity and blood pressure.
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were significantly more likely to have a low birthweight
infant after controlling for smoking and other socio-
demographic covariates [38].
Findings of this study provide additional data support-
ing the conclusion that light maternal smoking during
pregnancy may lead to reduced birthweight in infants.
Our results corroborate the results of other studies that
identification of the group of susceptible subjects should
be based on both environmental exposure and gene poly-
morphism and that the individual differences in metabolic
activation and detoxification of xenobiotics partly depends
on the genetic polymorphisms associated with the GST
enzymes [13-15,18,24,34]. When the GSTT1 genotype is
considered in smoking pregnant women, the three differ-
ent studies estimated reduction in birthweight among the
GSTT1–plus and GSTT1–null groups was as follows: 43 g
(P = 0.48) [14], 222 g (P < 0.05) [15], and 642 g (P < 0.001)
[13]. When the GSTM1 genotype is considered, the esti-
mated reduction in birthweight between GSTM1–plus and
GSTM1–null groups is 171 g (P = 0.04) [14] and 222 g
(P < 0.05), respectively [15]. The effects on the reduction
of birthweight are not observed among women with
GSTM1–null or GSTT1–null genotypes who had never
smoked and the data have been adjusted to the main con-
founding factors.
A combination of the GSTM1–null and the GSTT1–
null genotypes has been found to exacerbate the effect
of maternal exposure to environmental tobacco-smoking
on the birthweight of infants more than the presence of
either genotype alone. Our previous publicised study
have shown that when both GSTM1 and GSTT1 geno-
types were considered, the greater increase in low birth
weight and intra-uterine growth restriction risk was
found among smoking mothers with the GSTM1 geno-
type absent, OR 3.31 [95% CI 0.60, 18.4] and OR 2.47
[95% CI 0.31, 13.1], correspondingly [34].
We can postulate that the significant differences be-
tween the publicised studies, which are devoted to the
effects of tobacco-smoke exposure on birthweight, could
be attributed to the diverse ethnic composition of the
populations considered in the studies, resulting in differ-
ent distributions of the GST allelic frequency and different
levels of cigarette-smoke exposure, because dose–response
gradients in relation to the number of cigarettes smoked
do exist [19]. Furthermore, these results may be affected
by the residual uncontrolled confounding variables, such
as prepregnancy BMI, hypertension, stress level, gesta-
tional age and others, which are negatively or positively
associated with birthweight.
The main factors influencing birth-weight reduction are
gestational age and the organism’s response to toxicity from
environmental xenobiotics, such as tobacco PAHs. Tobacco
smoke toxins impair placental vasculature function andsubsequent transplacental transport of oxygen and nutri-
ents, and may lead to changes in vascular resistance
[39,40]. Reduction in blood flow increase apoptosis and it
is possible that this could be one of the mechanisms play-
ing a role in the growth restriction [41].
Several recent studies have investigating how genetic
susceptibility modulates risk of adverse pregnancy out-
comes from environmental exposures such as cigarette
smoke. Toxic chemicals could disturb foetal and placental
cellular regulation via elevated DNA adducts and DNA
damage [42]. Oxidative damage to placental DNA and
increased levels of 8-oxodG in placental DNA can result in
intrauterine growth restriction and low birthweight [43].
Maternal tobacco smoke exposure at an epigenome-wide
level is associated with placental gene expression and DNA
differential methylation and smoking-mediated birthweight
reduction [44].
It is likely that smoking mothers with high-risk geno-
types may have higher levels of PAH-DNA adducts and
DNA strand breakage due to the increased activity of
enzymes that metabolize cigarette toxins (e.g., CYP1A1
Aa and aa) and lower or absent activity of enzymes that
detoxify these compounds (e.g. GSTT1–null, GSTM1–null
genotypes) [45]. Moreover, such gene–smoking interac-
tions may exert their synergistic effects on birthweight
through maternal and foetal inflammatory responses and
immune responses [46]. As reported by some authors, ma-
ternal exposure to tobacco smoke induces oxidative stress.
Furthermore, maternal genetic polymorphisms related to
GSTM1 and GSTT1 may modify the oxidative stress
caused by maternal exposure to tobacco smoke [47].
We have investigated the genetic effects and the gene-
environment interaction by controlling for major con-
founding variables. This study has the advantage of
being the first to show that even light maternal smoking,
in association with double-null GSTT1 and GSTM1 gen-
otypes, might significantly decrease the infant birth-
weight. In this study, we estimated that the percentage
of GSTT1–null genotype was 17.2% and that of GSTM1
was 46.0%. The carriers of double-null genotypes were
8.7% of the total population studied.
When the results of this study are interpreted, a few
conditions should be considered. This is a low-risk popu-
lation with low-level tobacco smoke exposure (4.8 cig./
day) and low prevalence of GSTT1–null genotype; these
factors may limit the extrapolation of these results to other
populations. One of the limitations of the study is the rela-
tively small sample size with the GSTT1–null genotype.
The evaluation of exposure to tobacco smoke was indirect;
we used self-reported information on smoking during
pregnancy, and thus the possibility of bias in both report-
ing and exposure classification exists. We also examined
phase-II metabolic genes without study genes expressed in
phase-I. However, in this study, we controlled for the main
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maternal smoking, genetic polymorphism and birthweight;
therefore, the residual confounding of the results by smok-
ing is expected to be small. Despite these limitations, find-
ings of this study provide additional data supporting the
conclusion that maternal smoking during pregnancy may
lead to reduced birth weight in newborns.
Conclusion
The study shows the modifying effect of the GSTT1 and
GSTM1 genotypes on birthweight among smoking women
and presents evidence that carriers of the null genotypes
should be treated as an increased susceptibility group for
infant birthweight decrease. Our findings provide add-
itional insight into the biological determinants of response
to environmental exposure based on the combination of
genes and individual characteristics. Genotyping for the
GSTT1 and GSTM1 polymorphisms, simple and inexpen-
sive assays, could be suitable biomarkers identifying genet-
ically susceptible pregnant women. These risk stratification
markers could provide a valuable approach to estimate the
"causal" effects of risk behaviours with genetic-predisposing
factors (such as smoking) and could lead to targeted smok-
ing cessation interventions during pregnancy as prevention
for infants with low birthweight. The GSTT1–null geno-
type, either presents only one or both with GSTM1–null
genotype in a single subject, may have a modifying effect
on birthweight among smoking women even though their
smoking is low level. Our data also show that identification
of a susceptible-subject group should be based on both en-
vironmental exposure and gene polymorphism.
Competing interest
We confirm that all authors have no actual or potential competing interests
regarding the submitted article and the nature of those interests.
Authors’ contributions
AD was involved in primary data collection as well as the coding and
analysis of data, and the preparation of the manuscript. RG was involved in
the conceptualization of the research, the preparation of the manuscript. AP
contributed to genetic analysis. RD contributed to the development of the
survey instrument, contributed to data acquisition. MJN contributed to
qualitative data analysis and contributed to revisions of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported in part by grant FP6-036224 from the European
Commission. We acknowledge the contribution of the Clinics of Lithuanian
University of Health Science involved in registration of pregnancy outcomes.
Funding
This work was supported in part by grant FP6-036224 from the European
Commission.
Author details
1Department of Environmental Sciences, Vytautas Magnus University,
Donelaicio st. 58, 44248, Kaunas, Lithuania. 2Clinic of Obstetrics and
Gynecology, Lithuanian University of Health Science, Kaunas, Lithuania.
3Center for Research in Environmental Epidemiology (CREAL), Parc de
Recerca Biomedica de Barcelona – PRBB, Barcelona, Spain.Received: 27 June 2012 Accepted: 19 December 2012
Published: 26 December 2012
References
1. Stillerman KP, Mattison DR, Giudice LC, Woodruff TJ: Environmental
exposures and adverse pregnancy outcomes: a review of the science.
Reproductive Sci 2008, 15:631–650.
2. Lee BE, Hong YC, Park H, Ha M, Koo BS, Chang N, Roh YM, Kim BN, Kim YJ,
Kim BM, Jo SJ, Ha EH: Interaction between GSTM1/GSTT1 polymorphism
and blood mercury on birth weight. Environ Health Perspect 2010,
118:437–443.
3. Windham GC, Hopkins B, Fenster L, Swan SH: Prenatal active or passive
tobacco smoke exposure and the risk of preterm delivery or low birth
weight. Epidemiology 2000, 11:427–433.
4. Matijasevich A, Brion MJ, Menezes AM, Barros AJD, Santos IS, Barros FC:
Maternal smoking during pregnancy and offspring growth in childhood:
1993 and 2004 Pelotas cohort studies. Arch Dis Child 2011, 96:519–525.
5. Savitz DA, Dole N, Terry JW Jr, Zhou H, Thorp JM: Smoking and pregnancy
outcome among African-American and white women in central North
Carolina. Epidemiology 2001, 12:636–642.
6. Bolat F, Eren O, Bolat G, Can E, Cömert S, Uslu HS, Nuhoğlu A: Maternal
smoking during pregnancy and eff ects on neonatal anthropometry:
a prospective study. Turk J Med Sci 2012, 42:999–1005.
7. Varvarigou AA, Fouzas S, Beratis NG: Effect of prenatal tobacco smoke
exposure on fetal growth potential. J Perinat Med 2010, 38:683–687.
8. Pollack H, Lantz PM, Frohna JG: Maternal smoking and adverse birth
outcomes among singletons and twins. Am J Public Health 2000,
90:395–400.
9. Zeka A, Melly SJ, Schwartz J: The effects of socioeconomic status and
indices of physical environment on reduced birth weight and preterm
births in Eastern Massachusets. Environ Health 2008, 7:60.
10. Kukla L, Hruba D, Tyrlik M: Smoking and damages of reproduction:
evidence of ELSPAC. European longitudinal study of the pregnancy and
childhood. Cent Eur J Public Health 2001, 9:59–63.
11. Zhu BQ, Heeschen C, Sievers RE, Karliner JS, Parmley WW, Glantz SA, Cooke
JP: Second hand smoke stimulates tumor angiogenesis and growth.
Cancer Cell 2003, 4:191–196.
12. Sasaki S, Sata F, Katoh S, Saijo Y, Nakajima S, Washino N, Konishi K, Ban S,
Ishizuka M, Kishi R: Adverse birth outcomes associated with maternal
smoking and polymorphisms in the n-nitrosamine-metabolizing enzyme
genes NQO1 and CYP2E1. Am J Epidemiol 2008, 167:719–726.
13. Wang X, Zuckerman B, Pearson C, Kaufman G, Chen C, Wang G, Niu T, Wise
PH, Bauchner H, Xu X: Maternal cigarette smoking metabolic gene
polymorphism and infant birth weight. JAMA 2002, 287:195–202.
14. Sasaki S, Kondo T, Sata F, Saijo Y, Katoh S, Nakajima S, Ishizuka M, Fujita S,
Kishi R: Maternal smoking during pregnancy and genetic polymorphisms
in the Ah receptor, CYP1A1 and GSTM1 affect infant birth size in
Japanese subjects. Mol Hum Reprod 2006, 12:77–83.
15. Sram RJ, Binkova B, Dejmek J, Chvatalova I, Solansky I, Topinka J:
Association of DNA adducts and genotypes with birth weight. Mutat Res
2006, 608:121–128.
16. Infante-Rivard C, Weinberg CR, Guiguet M: Xenobiotic-metabolizing genes
and small-for-gestational-age births: interaction with maternal smoking.
Epidemiology 2006, 17:38–46.
17. Seidegard J, Ekstrom G: The role of human glutathione transferases and
epoxide hydrolases in the metabolisms of xenobiotics. Environ Health
Perspect 1997, 105:791–799.
18. Hong YC, Lee KH, Son BK, Ha EH, Moon HS, Ha M: Effects of the GSTM1
and GSTT1 polymorphisms on the relationship between maternal
exposure to environmental tobacco smoke and neonatal birth weight.
J Occup Environ Med 2003, 45:492–498.
19. Nukui T, Day RD, Sims CS, Ness RB, Romkes M: Maternal/newborn GSTT1
null genotype contributes to risk of preterm, low birthweight infants.
Pharmacogenetics 2004, 14:569–576.
20. Hayes JD, Strange RC: Glutathione S-transferase polymorphisms and their
biological consequences. Pharmacology 2000, 61:154–166.
21. Peter H, Deutschmann S, Reichel D, Hallier E: Metabolism of methyl
chloride by human erythrocytes. Arch Toxicol 1989, 63:351–355.
22. Warholm M, Rane A, Alexandrie AK, Monaghan G, Rannug A: Genotypic
and phenotypic determination of polymorphic glutathione transferase
T1 in a Swedish population. Pharmacogenetics 1995, 5:252–254.
Danileviciute et al. BMC Pregnancy and Childbirth 2012, 12:161 Page 10 of 10
http://www.biomedcentral.com/1471-2393/12/16123. Jain M, Kumar S, Rastogi N, Lal P, Ghoshal UC, Tiwari A, Pant MC, Baiq MQ,
Mittal B: GSTT1, GSTM1 and GSTP1 genetic polymorphisms and
interaction with tobacco, alcohol and occupational exposure in
esophageal cancer patients from North India. Cancer Lett 2006, 242:60–67.
24. Kishi R, Sata F, Yoshioka E, Ban S, Sasaki S, Konishi K, Washino N: Exploiting
gene-environment interaction to detect adverse health effects of
environmental chemicals on the next generation. Basic Clin Pharmacol
Toxicol 2008, 102:191–203.
25. Delpisheh A, Brabin L, Topping J, Reyad M, Tang AW, Brabin BJ: A case–control
study of CYP1A1, GSTT1 and GSTM1 gene polymorphisms, pregnancy
smoking and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2009,
143:38–42.
26. Chen X, Abdulhamid I, Woodcroft KJ: Maternal smoking during pregnancy,
polymorphic CYP1A1 and GSTM1, and lung-function measures in urban
family children. Environ Res 2011, 11:1215–1221.
27. Breton CV, Salam MT, Vora H, Gauderman WJ, Gilliland FD: Genetic variation in
the glutathione synthesis pathway, air pollution, and children’s lung
function growth. Am J Respir Crit Care Med 2011, 183:243–248.
28. Gilliland FD, Li YF, Dubeau L, Berhane K, Avol E, McConnell R, Gauderman
WJ, Peters JM: Effects of glutathione S-transferase M1, maternal smoking
during pregnancy, and environmental tobacco smoke on asthma and
wheezing in children. Am J Respir Crit Care Med 2002, 166:457–463.
29. Infante–Rivard C, Amre D, Sinnett D: GSTT1 and CYP2E1 polymorphisms
and trihalomethanes in drinking water: effect on childhood leukemia.
Environ Health Perspect 2002, 110:591–593.
30. Jurado D, Munoz C, Luna Jde D, Munoz-Hoyos A: Is maternal smoking
more determinant than paternal smoking on the respiratory symptoms
of young children? Respir Med 2005, 99:1138–1144.
31. Whyatt RM, Perera FP, Jedrychowski W, Santella RM, Garte S, Bell DA:
Association between polycyclic aromatic hydrocarbon-DNA adduct
levels in maternal and newborn white blood cells and glutathione
S-transfer- ase P1 and CYP1A1 polymorphisms. Cancer Epidemiol
Biomarkers Prev 2000, 9:207–212.
32. Dejmek J, Solansky I, Benes I, Lenícek J, Srám RJ: The impact of polycyclic
aromatic hydrocarbons and fine particles on pregnancy outcome.
Environ Health Perspect 2000, 108:1159–1164.
33. Chen X, Woodcroft KJ: Polymorphisms in metabolic genes CYP1A1 and
GSTM1 and changes in maternal smoking during pregnancy. Nicotine Tob
Res 2009, 11:225–233.
34. Grazuleviciene R, Danileviciute A, Nadisauskiene R, Vencloviene J: Maternal
Smoking, GSTM1 and GSTT1 polymorphism and susceptibility to adverse
pregnancy outcomes. Int J Environ Res Public Health 2009, 6:1282–1297.
35. Arand M, Mühlbauer R, Hengstler J, Jäger E, Fuchs J, Winkler L, Oesch F:
A multiplex polymerase chain reaction protocol for the simultaneous
analysis of the glutathione S-transferase GSTM1 and GSTT1
polymorphisms. Anal Biochem 1996, 236:184–186.
36. Hruba D, Kachlik P: Influence of maternal active and passive smoking
during pregnancy on birthweight in newborns. Cent Eur J Public Health
2000, 8:249–252.
37. Oberg S, Ge D, Cnattingius S, Svensson A, Treiber FA, Snieder H, Iliadou A:
Ethnic differences in the association of birth weight and blood pressure.
Am J Hypertens 2007, 20:1235–1241.
38. Brown SJ, Yelland JS, Sutherland GA, Baghurst PA, Robinson JS: Stressful life
events, social health issues and low birthweight in an Australian
population-based birth cohort: challenges and opportunities in
antenatal care. BMC Public Health 2011, 11:196.
39. Gandley RE, Jeyabalan A, Desai K, McGonigal S, Rohland J, DeLoia JA:
Cigarette exposure induces changes in maternal vascular function in a
pregnant mouse model. Am J Physiol Regul Integr Comp Physiol 2010,
298:R1249–R1256.
40. Machado Jde B, Plínio Filho VM, Petersen GO, Chatkin JM: Quantitative
effects of tobacco smoking exposure on the maternal-fetal circulation.
BMC Pregnancy Childbirth 2011, 31:11–24.
41. Voght Isaksen C: Maternal smoking, intrauterine growth restriction, and
placental apoptosis. Pediatr Dev Pathol 2004, 7:433–442.
42. Tsai HJ, Liu X, Mestan K, Yu Y, Zhang S, Fang Y, Pearson C, Ortiz K,
Zuckerman B, Bauchner H, Cerda S, Stubblefield PG, Xu X, Wang X:
Maternal cigarette smoking, metabolic gene polymorphisms, and
preterm delivery: new insights on GxE interactions and pathogenic
pathways. Hum Genet 2008, 123:359–369.43. Rossner PJ, Tabashidze N, Dostal M, Novakova Z, Chvatalova I, Spatova M,
Sram RJ: Genetic, biochemical, and environmental factors associated
with pregnancy outcomes in newborns from the Czech Republic. Environ
Health Perspect 2011, 119:265–271.
44. Suter M, Ma J, Harris AS, Patterson L, Brown KA, Shope C, Showalter L,
Abramovici A, Aagaard-Tillery KM: Maternal tobacco use modestly alters
correlated epigenome-wide placental DNA methylation and gene
expression. Epigenetics 2011, 6:1284–1294.
45. Perera FP, Rauh V, Whyatt RM, Tsai WY, Bernert JT, Tu YH, Andrews H,
Ramirez J, Qu L, Tang D: Molecular evidence of an interaction between
prenatal environmental exposures and birth outcomes in a multiethnic
population. Environ Health Perspect 2004, 112:626–630.
46. Noakes PS, Holt PG, Prescott SL: Maternal smoking in pregnancy alters
neonatal cytokine responses. Allergy 2003, 58:1053–1058.
47. Park EY, Hong YC, Lee KH, Im MW, Ha E, Kim YJ, Ha M: Maternal exposure
to environmental tobacco smoke, GSTM1/T1 polymorphism and
oxidative stress. Reprod Toxicol 2008, 26:197–202.
doi:10.1186/1471-2393-12-161
Cite this article as: Danileviciute et al.: Low level maternal smoking and
infant birthweight reduction: genetic contributions of GSTT1 and GSTM1
polymorphisms. BMC Pregnancy and Childbirth 2012 12:161.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
